Patent life of antiretroviral drugs approved in the US from 1987 to 2007

References

• Attaran , A. 2004 . How do patents and economic policies affect access to essential medicines in developing countries? . Health Affairs , 23 ( 3 ) : 155 – 166 .
   Web of Science ®Google Scholar
• Attaran , A. and Gillespie-White , L. 2001 . Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa? . Journal of the American Medical Association , 286 : 1886 – 1892 .
   Web of Science ®Google Scholar
• Brugha , R. 2003 . Antiretroviral treatment in developing countries: the peril of neglecting private providers . British Medical Journal , 326 : 1382 – 1384 .
   PubMed Web of Science ®Google Scholar
• Caves R.E ., Whinston M.D ., Hurwitz M.A ., Pakes A ., & Temin P . 1991 . Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry. Brookings Papers on Economic Activity . Microeconomics , 1991 , 1 – 66 .
   Google Scholar
• Creese , A. , Floyd , K. , Alban , A. and Guinness , L. 2002 . Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence . Lancet , 359 : 1635 – 1643 .
   PubMed Web of Science ®Google Scholar
• Eisenberg , R.S. 2001 . The shifting functional balance of patents and drug regulation . Health Affairs , 19 ( 4 ) : 119 – 135 .
   Google Scholar
• Eisman , M.M. and Wardell , W.M. 1981 . The decline in effective patent life of new drugs . Research Management , 21 ( 1 ) : 18 – 21 .
   Google Scholar
• Ford , N. , Wilson , D. , Costa Chaves , G. , Lotrowska , M. and Kijtiwatchakul , K. 2007 . Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand . AIDS , 21 ( Suppl. 4 ) : S21 – S29 .
   PubMedGoogle Scholar
• Grabowski , H.G. and Vernon , J.M. 1996 . Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade . Pharmacoeconomics , 10 ( 2 ) : 110 – 123 .
   PubMed Web of Science ®Google Scholar
• Grabowski , H.G. and Vernon , J.M. 2000 . Effective patent life in pharmaceuticals . International Journal of Technology Management , 19 ( 1/2 ) : 98 – 120 .
   Web of Science ®Google Scholar
• Griliches , Z. and Cockburn , I. 1994 . Generics and new goods in pharmaceutical price indexes . American Economic Review , 84 ( 5 ) : 1213 – 1233 .
   Web of Science ®Google Scholar
• Kates , J. , Sorian , R. , Crowley , J.S. and Summers , T.A. 2002 . Critical policy challenges in the third decade of the HIV/AIDS epidemic . American Journal of Public Health , 92 : 1060 – 1063 .
   PubMed Web of Science ®Google Scholar
• Kesselheim , A.S. 2007 . Intellectual property policy in the pharmaceutical sciences: The effect of inappropriate patents and market exclusivity extensions on the health care system . The AAPS Journal , 9 ( 3 ) : E306 – E311 .
   PubMed Web of Science ®Google Scholar
• Kober , K. and Van Damme , W. 2004 . Scaling up access to antiretroviral treatment in southern Africa: Who will do the job? . Lancet , 364 : 103 – 107 .
   PubMed Web of Science ®Google Scholar
• Mansfield , E. 1986 . Patents and innovation: An empirical study . Management Science , 32 : 173 – 181 .
   Web of Science ®Google Scholar
• Nordhaus , W.D. 1969 . Invention growth, and economic welfare; a theoretical treatment of technological change , Cambridge , MA : MIT Press .
   Google Scholar
• Seoane-Vazquez , E. and Rodriguez-Monguio , R. 2007 . Negotiating antiretroviral drug prices: The experience of the Andean countries . Health Policy and Planning , 22 ( 2 ) : 63 – 72 .
   PubMed Web of Science ®Google Scholar
• Seoane-Vazquez , E. , Schondelmeyer , S.W. and Szeinbach , S.L. 2008 . Drug patent live and generic competition: Analysis of new molecular entities approved by the FDA between 1980 and 1999 . Journal of Pharmaceutical Finance, Economics & Policy , 16 ( 4 ) : 67 – 85 .
   Google Scholar
• Wainberg , M.A. 2005 . Generic HIV drugs: Enlightened policy for global health . New England Journal of Medicine , 352 ( 8 ) : 747 – 750 .
   PubMed Web of Science ®Google Scholar